Vaxxinity Temettü

Temettü kriter kontrolleri 0/6

Vaxxinity şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.45
Gelecekteki Temettü Verimi	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Jan 08

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Sep 12

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: VAXX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: VAXX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Vaxxinity Piyasaya Karşı Temettü Getirisi

VAXX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (VAXX)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.5%
Sektör Ortalaması (Biotechs)	2.2%
Analist tahmini (VAXX) (3 yıla kadar)	0%

Önemli Temettü: VAXX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, VAXX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: VAXX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: VAXX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Vaxxinity Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine

Vaxxinity Files Form 15

Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024

Vaxxinity, Inc. Receives A Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies

Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors

New major risk - Financial position

High number of new directors

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease

New minor risk - Financial position

Vaxxinity, Inc. Announces Executive Changes

Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease

Non-Employee Independent Director exercised options to buy US$1.0m worth of stock.

Less than half of directors are independent

Vaxxinity, Inc. Announces the Relocation of its Corporate Headquarters

A Look At The Intrinsic Value Of Vaxxinity, Inc. (NASDAQ:VAXX)

Vaxxinity Announces Positive Topline Pivotal Phase 3 COVID-19 Booster Data for UB-612

Price target decreased to US$13.50

Less than half of directors are independent

Price target decreased to US$13.50

Vaxxinity Completes Enrollment in Pivotal Phase 3 Clinical Trial of UB-612 COVID-19 Vaccine Heterologous Booster Candidate and Initiates Rolling Submission for Provisional Approval in Australia

Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine

Vaxxinity initiates rolling submission for its COVID-19 shot with UK's drug regulator

Vaxxinity's Anti-PCSK9 Candidate Demonstrates Durable LDL Cholesterol Lowering in Non Human Primates

Vaxxinity, Inc. Presents Preclinical Data on Tau Vaccine Candidates At the 2022 Alzheimer's Association International Conference

Less than half of directors are independent

The Coalition for Epidemic Preparedness Innovations to Co-Fund Vaxxinity, Inc.'s Pivotal Phase 3 UB-612 Heterologous Booster Trial to Combat SARS-CoV-2 variants

Less than half of directors are independent

Vaxxinity, Inc. Announces First Participant Dosed in Phase 3 Study of Next-Generation Covid-19 Vaccine Booster

Vaxxinity’s COVID-19 Vaccine Candidate UB-612 Produces High Levels of Neutralizing Antibodies Against Omicron and Other Variants of Concern

Vaxxinity, Inc. Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Non-Employee Independent Director recently bought US$63k worth of stock

Co-Founder & Executive Chairman recently bought US$242k worth of stock

Less than half of directors are independent

Second quarter 2021 earnings released: US$0.39 loss per share

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin